Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Fig. 1

Percentage change from baseline to week 24 in non-HDL-C, LDL-C, ApoB, LDL-PN (ITT). Apo apolipoprotein, HDL-C high-density lipoprotein cholesterol, ITT intent-to-treat, LDL-C low-density lipoprotein cholesterol, LDL-PN low-density lipoprotein particle number, LS least-squares, SE standard error, UC usual care

Back to article page